Scientific program

Session Key:

Pre-Congress Workshop Plenary Session Parallel Session Free Papers Session Industry Symposium

Thursday, October 14, 2021

08:30-11:50 Pre-Congress Workshop 1: Hall B
Chairperson
08:30-10:00 Workshop 1
10:00-10:20 Coffee Break 
10:20-11:50 Workshop 1 continued
 08:30-11:50 Pre-Congress Workshop 2: Hall C
Chairperson
08:30-10:00 Workshop 2
10:00-10:20 Coffee Break 
10:20-11:50 Workshop 2 continued
 08:30-11:50 Pre-Congress Workshop 3: Hall D
Chairperson
08:30-10:00 Workshop 3
10:00-10:20 Coffee Break 
10:20-11:50 Workshop 3 continued
12:30-13:30 Lunch Break 
 12:50-16:10 Pre-Congress Workshop 4: Hall B
Chairperson
12:50-14:20 Workshop 4
14:20-14:40 Coffee Break 
14:40-16:10 Workshop 4 continued
12:50-16:10 Pre-Congress Workshop 5: Hall C
Chairperson
12:50-14:20 Workshop 5
14:20-14:40 Coffee Break 
14:40-16:10 Workshop 5 continued
12:50-16:10 Pre-Congress Workshop 6: Hall D
Chairperson
12:50-14:20 Workshop 6
14:20-14:40 Coffee Break 
14:40-16:10 Workshop 6 continued
 16:30-16:45 Congress Opening Hall A
 16:45-18:15 Plenary Session 1:
Neoadjuvant therapy
Hall A
Chairpersons
 16:45-17:15
16:45
16:55
17:05
Debate: That cT1cN0 HER2+ve and TNBC should have NAST
Yes:
No: Nicholas Wilcken, Australia
Discussion
 17:15-17:45 Experience of NAET during COVID in the UK
TBA
 17:45-18:15
17:45
17:55
18:05
Debate:That LN positive patients achieving pCR with NAST should still receive regional nodal radiotherapy
Yes: Phillip Poortmans, Belgium
No: 
Discussion
 18:15 Networking Reception

Friday, October 15, 2021

07:00-08:30 Morning Industry Symposium: 
Supported by AstraZeneca
Breakfast will be served prior to the session
Hall A
07:00-08:30 Morning Industry Symposium: 
Supported by Genesis Care and Prelude
Breakfast will be served prior to the session
Hall B
 08:30-09:30 Parallel Session 2:
Screening
Hall A
 Chairpersons
 08:30-09:05
08:30
08:40
08:50
Debate: That women at low risk for breast cancer should only be screened every 5 years
Yes: Christobel Saunders,Australia
No: Jane Fox, Australia
Discussion
 09:00-09:30 Risk adjusted screening: Lessons from COVID
Carolyn Nickson, Australia
 08:30-09:30 Parallel Session 3:
Fear of cancer recurrence
Hall B
Chairpersons
 08:30-09:30 Parallel Session 4:
Free Papers: Medical oncology
Hall C
Chairpersons
 09:30-11:00 Plenary Session 5:
Genetics
Hall A
 Chairpersons
 09:30-10:10
09:30
09:45
10:00
Debate: That ~all patients with breast cancer should be panel tested for germline mutations
Yes: 
No: 
Discussion
10:10-10:35 The ‘new genes’: What do they mean for patients and families?
Paul James, Australia
10:35-11:00 Tailored treatments for BRCA+ early breast cancer: The time is now!
Mark Robson, USA
11:00-11:30 Coffee break and poster viewing
 11:30-12:30 Parallel Session 6:
Lymphoedema
Hall A
 Chairpersons
 11:30-11:50 What is the evidence behind advice regarding lymphoedema prevention?
Louise Koelmeyer, Australia
11:50-12:10 Evidence based treatment modalities for established lymphoedema: What works? What doesn’t?
Robyn Box, Australia
 12:10-12:30 Discussion
11:30-12:30 Industry Symposium: 
Supported by TBA
Hall B
 11:30-12:30 Industry Symposium:
Supported by OncoRes
Hall C
12:30-13:30 Lunch break  and poster viewing
 13:30-14:30 Parallel Session 7:
DCIS
Hall A
 Chairpersons
 13:30-14:00
13:30
13:40
13:50
Debate: That most patients with DCIS should not have radiotherapy after Breast Conserving Surgery
Yes: Alastair Thompson, USA
No: Boon Chua, Australia
Discussion
 
14:00-14:30
14:00
14:10
14:20
Debate: That active surveillance for low risk DCIS is a reasonable option
Yes: Jocelyn Lippey, Australia
No: 
Discussion
13:30-14:30 Parallel Session 8:
Triple negative breast cancer

Hall B
 Chairpersons
13:30-14:10
13:30
13:45
14:00
Debate: Immunotherapy should be part of standard of care for 1st line TN MBC
Yes: Sherene Loi, Australia
No: Rebecca Dent, Singapore
Discussion
14:15-14:30 TNBC subtypes and their clinical significance
Nirmala Pathmanathan, Australia
 13:30-14:30 Parallel Session 9: Free Papers: Surgical Hall C
 Chairperson
 14:30-15:50 Plenary Session 10:
Adjuvant endocrine therapy
Hall A
Chairpersons  
14:30-15:05
14:30
14:40
14:50
Debate: That CDK4/6i’s should be part of adjuvant treatment of high risk ER+HER2- early breast cancer
Yes: Shom Goel, Australia
No: Nick Zdenkowski, Australia
Discussion
15:05-15:15 Update on topic estrogens in symptomatic women with early breast
Belinda Kiely, Australia
15:15-15:50
15:15
15:25
15:35
Debate: That all pre-menopausal women with LN+ve ER+her2- EBC should have adjuvant chemotherapy
Yes: Nicole McCarthy, Australia
No: Belinda Yeo, Australia
Discussion
15:50-16:10 Coffee break and poster viewing
 16:10-17:30 Parallel Session 11:
Imaging
Hall A
Chairpersons
16:10-16:40
16:10
16:20
16:30
Debate: That PET/CT should be the standard staging investigation for Stage 2/3 early breast cancer
Yes: 
No: 
Discussion
16:40-17:10
16:40
16:50
17:00
Debate: That routine contrast imaging should be part of the workup of early breast cancer
Yes: Bruce Mann, Australia
No: Owen Ung, Australia
Discussion
17:10-17:30 That CEM is ready for prime time
TBA
16:10-17:30 Parallel Session 12: 
Metastatic breast cancer
Hall B
Chairperson
16:10-16:45
16:10
16:20
16:30
Debate: That molecular testing of tumours should be routine for those with metastatic breast cancer
Yes: Elgene Lim, Australia
No: Sarah-Jane Dawson, Australia
Discussion
16:45-17:30
16:45
16:55
17:05
Debate: Routine imaging vs clinical follow-up for high risk EBC: Time to change the paradigm?
Yes: 
No: Catherine Shannon, Australia
Discussion

 

 13:30-14:30 Parallel Session 13: Free Papers: Supportive Care Hall C
 Chairperson

Saturday, October 16, 2021

07:00- 8:30 Morning Industry Symposium: 
Supported by Endomag/Ebos
Breakfast will be served prior to the session
Hall A
07:00-08:30 Morning Industry Symposium: Attractive techniques for localisation and staging: Tools for everyone
Supported by TBA
Breakfast will be served prior to the session
Hall B
 08:30-10:00 Parallel Session 14:
Controversies in reconstruction
Hall A
Chairpersons
 08:30-09:10
08:30
08:40
08:50
Debate: That immediate breast reconstruction prior to post-mastectomy radiotherapy should be avoided
Yes: Caroline Baker, Australia
No: Dean Trotter, Australia
Discussion
 09:10-09:30 Patient-reported outcomes to guide decisions regarding breast reconstruction
Douglas MacMillan, UK
09:30-09:50 Shared decision making is desirable around breast reconstruction: How can it be achieved?
TBA
09:50-10:00 Discussion
 08:30-10:00 Parallel Session 15:
Survivorship
Hall B
 Chairpersons
08:30-08:35 Introduction
08:35-08:45 Survivorship MoC based around nurse led clinics
Kerry Shanahan, Australia
08:45-08:55 McGrath model of survivorship care
Kerry Patford, Australia
08:55-09:05 GP perspective
TBA
09:05-09:15 IBIS
Ray Chan, Australia
09:15-10:00 Discussion
 10:00-11:00 Parallel Session 16:
Locoregional therapy
Hall A
Chairpersons
 10:00-10:30
10:00
10:10
10:20
Debate: That patients with heavy axillary nodal disease pre-NACT should have axillary dissection irrespective of response to NACT
Yes: Alastair Thompson, USA
No: Ben Green, Australia
Discussion
 10:30-11:00
10:30
10:40
10:50
Debate: That omission of SNB should be considered for all women >70 with clinically negative axillae
Yes: Melanie Walker, Australia
No: Sanjay Warrier, Australia
Discussion
10:00-11:00 Parallel Session 17:
HER2 positive disease
Hall B
Chairpersons
10:00-10:40
10:00
10:15
10:30
Debate: In the KATHERINE era, neoadjuvant pertuzumab is redundant
Yes: Shane White, Australia
No: TBA
Discussion
 10:40-11:00 HER2 heterogeneity: Interpretation of low HER2 amplification and HER+ve hotspots
Cameron Snell, Australia
11:00-11:30 Coffee break and poster viewing
 11:30-13:00 Parallel Session 18:
Local therapy
Hall A
Chairpersons
11:30-12:30 Time to cut the wire?
 11:30 Hook needles and/or carbon is perfectly satisfactory
Christopher Pyke, Australia
11:40 The case for SCOUT
TBA
11:50 The case for Magseed
TBA
12:00 The case for Rollis
Rhea Liang, Australia
12:10 Discussion
12:30-13:00
12:30
12:40
12:50
Debate: That five-fraction radiotherapy should be standard of care for most patients
Yes: 
No: Frank A. Vicini, USA
Discussion
11:30-13:00 Industry Symposium: 
Supported by TBA
Hall B
10:30-13:00 Breast Cancer Network Australia 
Hall C
13:00-14:00 Lunch break and poster viewing
 14:00-15:00 Plenary Session 19:
Palliative care
Hall A
Chairpersons
14:00-14:30
14:00
14:10
14:20
Debate: That palliative care should ditch the word ‘palliative’
Yes: Brian Le, Australia
No: Andrew Broadbent, USA
Discussion
14:30-15:00 Medicinal cannabis
Phillip Good, Australia
 15:00-16:15 Plenary Session 20:
Breast Cancer 2030
Hall A
 Chairpersons
15:00-15:15 Early detection
Ritse Mann, The Netherlands
15:15-15:30 A pathologist’s view of breast cancer in 2030
Sunil R. Lakhani, Australia
15:30-15:45 Systemic therapy
Prudence Francis, Australia
15:45-16:00 Locoregional therapy
Elisabeth Elder, Australia
16:00-16:15 A consumer’s perspective of breast cancer in 2030
Kirsten Pilatti, Australia
16:15-16:30 Congress closing and Award presentation
Hall A
 Chairpersons Bruce Mann, Australia
Melanie Walker, Australia
Elisabeth Elder, Australia